Why a dead-clean sterile filter can pass pyrogen straight through

Bacterial endotoxin is the single most under-discussed contaminant in this market, and the reason is that it does not behave like the contaminants people intuitively worry about. It is not alive. It is a lipopolysaccharide fragment of the outer membrane of Gram-negative bacteria, released in quantity when those bacteria die. It is thermostable enough to survive an autoclave cycle comfortably, small enough to pass a 0.22 micron sterilising filter without hindrance, and pyrogenic in the low nanogram range. A preparation can be perfectly sterile — no viable organism anywhere in the container — and carry an endotoxin burden well above any defensible parenteral limit.

Bioburden, and why the number before the filter matters

A sterilising filter is not an unlimited barrier. Its qualification is expressed as a retention capability under a defined challenge — conventionally a high titre of a small bacterial species per square centimetre of membrane — and its performance in use depends on the load presented to it. A bulk solution carrying a heavy microbial burden presents a filter with a harder problem than one carrying a light burden, and it presents a second problem the filter cannot address at all: the endotoxin released by organisms that die upstream passes through the membrane unimpeded.

Regulated manufacture therefore specifies a pre-filtration bioburden limit, tests against it on every batch, and treats an excursion as an investigation rather than a curiosity. The specification is usually expressed in colony-forming units per hundred millilitres, and a well-controlled process runs far below it.

Of the twenty companies the Journal wrote to, four stated that pre-filtration bioburden is determined on every batch, three stated that it is determined periodically, and the remainder did not answer the question. We regard that distribution as the single most informative result of the correspondence, because bioburden testing is inexpensive, is performed on the bulk rather than the finished container, and is the earliest point at which a problem is cheap to fix.

What endotoxin is, and why sterility does not address it

Endotoxin is a structural component of the outer membrane of Gram-negative bacteria: a lipopolysaccharide with a lipid A anchor that is the pyrogenic moiety, a core oligosaccharide, and a variable O-antigen chain. It is shed during growth and released in quantity on cell lysis, which means that killing a bacterial population does not remove its endotoxin and may increase the free concentration.

Three physical properties make it a separate discipline. It is thermally robust, surviving autoclave conditions with little loss of pyrogenicity, so terminal sterilisation is not a depyrogenation step. It is small and amphipathic, forming aggregates that pass a 0.22 micron membrane without difficulty, so sterilising filtration is not a depyrogenation step either. And it is active in humans at very low mass — the threshold pyrogenic dose corresponds to something in the region of a nanogram per kilogram of body weight.

The practical consequence is stark. A vial can pass a sterility test, contain no viable organism of any kind, and carry an endotoxin burden many times a defensible parenteral limit, because the organisms responsible died somewhere upstream in a water system, a holding tank or a poorly stored component.¹

Three method families, and what each returns

The gel-clot method is the oldest and simplest: lysate is combined with the sample, incubated, and the tube inverted. A firm clot that does not slip is a positive. It is a limit test, and by testing serial dilutions it becomes semi-quantitative. Its virtues are robustness and independence from instrumentation; its limitation is resolution.

Turbidimetric methods read the increasing turbidity produced by clotting protein formation, either as an endpoint at fixed time or kinetically as the time to reach a defined turbidity. Chromogenic methods substitute a synthetic peptide substrate that releases a chromophore when cleaved by the activated enzyme, and read absorbance. The kinetic chromogenic variant — measuring the time to a defined absorbance change against a standard curve — is the method of record for most modern release testing, offering quantitation across several orders of magnitude from a small sample volume.

All three are compendial, all three require a demonstration that the sample matrix neither inhibits nor enhances the reaction, and all three are calibrated against an international reference endotoxin rather than against a mass. A result reported without the method and without the inhibition-enhancement result is, once again, a number without a procedure.²

Recombinant factor C, and the end of an awkward supply chain

The lysate on which conventional endotoxin testing depends is harvested from horseshoe crabs, which are bled and returned to the sea with a mortality that is disputed and not negligible. The assay also inherits the biological variability of a natural product: lysate lots differ, and the cascade includes a branch responsive to beta-glucans, which is a common source of false positives in the presence of cellulose filter residues.

Recombinant factor C reagents replace the harvested cascade with an expressed enzyme, activated by lipopolysaccharide and read chromogenically or fluorimetrically. The response is specific to endotoxin and insensitive to the glucan branch, lot-to-lot consistency is a manufacturing rather than an ecological question, and comparative studies across a wide range of matrices have found agreement with conventional methods well within the variability of the conventional methods themselves.

The reagent has been available for well over a decade and its slow adoption was a regulatory rather than a scientific matter: for years it sat in an alternative-method chapter, obliging users to validate it as a departure. That has now changed, with dedicated chapters in both the United States and European compendia treating recombinant reagents as methods in their own right, and the Journal expects the harvested lysate to become the historical option within this decade.³⁴

The endotoxin limit, calculated

The limit is derived, not looked up. For a parenteral product other than an intrathecal one, the threshold pyrogenic dose is taken as five endotoxin units per kilogram of body weight per hour. The endotoxin limit for the product is that figure divided by the maximum dose per kilogram administered within an hour. For an intrathecal route the threshold falls to 0.2 endotoxin units per kilogram, a twenty-five-fold reduction that reflects the absence of the systemic buffering the bloodstream provides.

Work it for a concrete case. A seventy-kilogram subject has an hourly allowance of three hundred and fifty endotoxin units. A vial nominally containing five milligrams of peptide, reconstituted to two millilitres, from which a fifth of a millilitre is drawn, delivers a tenth of the vial contents. If the whole vial carried three hundred and fifty endotoxin units, that draw would deliver thirty-five — a tenth of the allowance. The limit expressed per milligram of peptide is what a certificate should carry, because it is the only form of the number that survives a change in reconstitution volume.

None of the arithmetic is difficult. What is missing from this trade is not the calculation but the measured numerator.⁵

Low endotoxin recovery, and the clean result that is wrong

The most uncomfortable finding in endotoxin testing over the past fifteen years is that certain formulation matrices cause added endotoxin to become undetectable over time. Spike a known quantity of reference endotoxin into a solution containing a non-ionic surfactant and a chelating buffer, hold it, and the recoverable endotoxin declines — sometimes to a small fraction of what was added — while nothing has been removed. The lipopolysaccharide aggregate state has changed, and the assay cannot see what it cannot bind.

The phenomenon is called low endotoxin recovery, and it matters because the combination of polysorbate with citrate or phosphate is extremely common in peptide and protein formulations. A hold-time study — spiking the actual product matrix and measuring recovery across the intended sample storage interval — is the standard mitigation, and it is now expected as part of method suitability for products in that formulation space.

The implication for a reader is narrow but worth stating. A negative endotoxin result on a surfactant-containing formulation, reported without a hold-time recovery study, is weaker evidence than it appears. A negative result on a reconstituted lyophilised peptide in plain water for injection, tested promptly, is considerably stronger.⁶

Depyrogenation, and the step that gets skipped

Because endotoxin survives sterilisation, glass components require a separate treatment. The standard is dry heat: a tunnel or oven cycle at two hundred and fifty degrees or above, validated to achieve at least a three-log reduction in a deliberately applied endotoxin challenge. Vials emerging from a qualified depyrogenation tunnel are both sterile and pyrogen-free, and they remain so only if the subsequent handling maintains it.

Elastomeric closures cannot take that treatment and are instead washed, siliconised and steam-sterilised by a validated cycle, with endotoxin control achieved by the washing step and specified as a limit per stopper. Water for injection is controlled at source, with a compendial endotoxin specification, and a water system is the commonest origin of a pyrogen problem in an otherwise competent facility.

Depyrogenation is also, in the Journal’s experience of asking, the step most frequently absent from descriptions of small fill operations. Autoclaved vials are sterile. Autoclaved vials are not depyrogenated, and an operation that describes its glass preparation solely in terms of autoclaving has told you something specific about what it has not done. We put this point to eleven correspondents; two said their glass is depyrogenated by dry heat with a validated cycle, and one asked us what depyrogenation was, which we took as a straight answer and a useful one.

Fourth puncture, fifth puncture: the elastomer as a physical object

A multiple-dose closure is engineered to reseal after a defined number of penetrations by a needle of defined gauge, and the qualification data behind that claim is generated with a specific needle geometry at a specific rate. Beyond that number, the resealing behaviour is not characterised, and the failure is not usually dramatic: the elastomer simply stops closing fully behind the needle track.

Two related phenomena deserve naming. Coring is the removal of a fragment of elastomer by the needle tip, which both leaves a particle in the solution and creates a channel that does not reseal. It is more likely with larger-gauge needles, with repeated penetration through the same point, and with a needle that has already been used and blunted. Fragmentation testing is a compendial requirement for elastomeric closures precisely because of it.

The practical inference available to a reader is not a recommendation, because this publication does not make those. It is an observation about the object: a closure has a puncture budget, that budget is a number somebody determined experimentally, nobody in this trade publishes it, and the elastomer behaves according to the number rather than according to what anybody assumed. Rotating the entry point and using a fresh needle each time are answers to a mechanical problem, not to a microbiological one.

What we submitted, and what came back

Between the second and fourth quarters the Journal purchased fourteen vials of lyophilised research peptide from nine suppliers, at catalogue prices, through ordinary channels and without identifying ourselves. Each was photographed sealed, logged, and stored at two to eight degrees on arrival. Twelve were submitted to a contract laboratory accredited to the general competence standard for testing laboratories for bacterial endotoxin determination by kinetic chromogenic assay, with method suitability established for each matrix. Two were submitted for a compendial sterility test by membrane filtration, which destroyed both.

We disclose the following limitations without being asked. Fourteen vials from nine suppliers is not a survey. Single determinations carry the uncertainty of single determinations. A negative sterility result on one vial says nothing about the batch it came from, for exactly the statistical reasons set out above. And a vial that has crossed a border in a padded envelope has a thermal and mechanical history we cannot reconstruct.

What the exercise establishes is narrower than a survey and, we think, worth publishing: that the tests exist, that they are commercially available to a private purchaser at a known price, that the numbers they return are interpretable against a calculable limit, and that nothing prevented any of the nine suppliers from commissioning them first.⁷

What this article is not asserting

Precision about the scope of a criticism is part of the job, so it is worth spending a paragraph on what is not being said. This piece does not allege that any company named in it has sold contaminated material. It does not allege that any of them has concealed a result, falsified a document or misrepresented a test. It does not claim that the products discussed are dangerous, and it does not claim that they are safe, because neither claim is supportable from the evidence we have.

What the piece asserts is documentary. A certificate describing chemistry is being read as a release package covering microbiology. That mismatch is created by the format of the document rather than by anybody’s intent, and it is closed by adding lines rather than by changing behaviour.

There is also a legal point the Journal has no wish to elide. Research-use-only material is not approved for human use in any jurisdiction, is not required to meet parenteral standards, and is not represented by its sellers as meeting them. Everything in this article about endotoxin limits and sterility assurance describes the framework that would apply to a parenteral medicine. Applying that framework to a research chemical is a comparison, not a compliance requirement, and readers should hold both halves of that sentence at once.

A note on method and sourcing

The compendial material in this article is drawn from the current general chapters of the United States Pharmacopeia and the European Pharmacopoeia, read in the original rather than in summary, and from the international standards on aseptic processing and on laboratory competence. Where a chapter has changed status recently — as the recombinant reagent chapters have — we say so, because a reader consulting an older edition will find a different framing.

Where the Journal reports a number it obtained itself, it states the laboratory’s accreditation status, the method family, whether method suitability was established, and the number of determinations. Where we report what a company told us, we distinguish an answer from a refusal and a refusal from a non-response, because those three things are routinely collapsed in coverage of this trade and they are not the same.

Corrections to this department are handled by the standards desk, which reads every letter and records the outcome in the log. Readers who believe a paragraph here overstates its evidence are asked to write to standards@compoundjournal.com; readers with documents to send, including certificates they would like read, should write to letters@compoundjournal.com. We do not publish correspondents’ names without permission and we do not identify the source of a certificate.

Readers should hold two facts together, uncomfortable as the combination is. The frameworks described here — endotoxin limits, sterility assurance, particulate ceilings — govern licensed parenteral medicines, and research-use material is under no obligation to meet them. That is a legal fact about obligation. It is not a reassurance, and nobody involved in the trade has ever suggested it was.